These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 37433404)

  • 1. Strategy of dual antiplatelet therapy for patients with ST-elevation myocardial infarction and non-ST-elevation acute coronary syndromes: A systematic review and network meta-analysis.
    Saito T; Fujisaki T; Aikawa T; Kampaktsis PN; Malik A; Briasoulis A; Takagi H; Wiley J; Slipczuk L; Kuno T
    Int J Cardiol; 2023 Oct; 389():131157. PubMed ID: 37433404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
    De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
    BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
    Kuno T; Watanabe A; Shoji S; Fujisaki T; Ueyama H; Takagi H; Deharo P; Cuisset T; Bangalore S; Mehran R; Stone GW; Kohsaka S; Bhatt DL
    Circ Cardiovasc Interv; 2023 Sep; 16(9):e013242. PubMed ID: 37609850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.
    Tavenier AH; Mehran R; Chiarito M; Cao D; Pivato CA; Nicolas J; Beerkens F; Nardin M; Sartori S; Baber U; Angiolillo DJ; Capodanno D; Valgimigli M; Hermanides RS; van 't Hof AWJ; Ten Berg JM; Chang K; Kini AS; Sharma SK; Dangas G
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):492-502. PubMed ID: 34459481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
    Kuno T; Fujisaki T; Shoji S; Sahashi Y; Tsugawa Y; Iwagami M; Takagi H; Briasoulis A; Deharo P; Cuisset T; Latib A; Kohsaka S; Bhatt DL
    Circ Cardiovasc Interv; 2022 Aug; 15(8):e011990. PubMed ID: 35899618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial.
    Obayashi Y; Natsuaki M; Watanabe H; Morimoto T; Yamamoto K; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tokuyama H; Sakamoto H; Fujita T; Nanasato M; Okayama H; Nishikura T; Kirigaya H; Nishida K; Ono K; Kimura T;
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):374-390. PubMed ID: 38285607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Net clinical benefit of dual antiplatelet therapy in elderly patients with acute coronary syndrome: A systematic review and meta-analysis.
    Fujisaki T; Kuno T; Iwagami M; Miyamoto Y; Takagi H; Deharo P; Cuisset T; Briasoulis A; Panaich S; Latib A; Kohsaka S
    Catheter Cardiovasc Interv; 2023 Nov; 102(5):788-802. PubMed ID: 37675959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.
    Kang J; Rizas KD; Park KW; Chung J; van den Broek W; Claassens DMF; Choo EH; Aradi D; Massberg S; Hwang D; Han JK; Yang HM; Kang HJ; Chang K; Ten Berg JM; Sibbing D; Koo BK; Kim HS
    Eur Heart J; 2023 Apr; 44(15):1360-1370. PubMed ID: 36883613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De-Escalation Dual Antiplatelet Therapy Prevail over Potent P2Y12 Inhibitor Monotherapy in Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Ding JW; Chen Y; Yu ZZ; Zhao YB; Fan KP; Yao XD; Hu LL; Liao YH; Deng TH; Xia Y; Liao HH; Yang RQ
    Rev Cardiovasc Med; 2022 Nov; 23(11):360. PubMed ID: 39076186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
    Shoji S; Kuno T; Fujisaki T; Takagi H; Briasoulis A; Deharo P; Cuisset T; Latib A; Kohsaka S
    J Am Coll Cardiol; 2021 Aug; 78(8):763-777. PubMed ID: 34275697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
    Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
    Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
    Watanabe H; Morimoto T; Natsuaki M; Yamamoto K; Obayashi Y; Ogita M; Suwa S; Isawa T; Domei T; Yamaji K; Tatsushima S; Watanabe H; Ohya M; Tokuyama H; Tada T; Sakamoto H; Mori H; Suzuki H; Nishikura T; Wakabayashi K; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA Cardiol; 2022 Apr; 7(4):407-417. PubMed ID: 35234821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.
    Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW
    Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
    Fujisaki T; Kuno T; Briasoulis A; Misumida N; Takagi H; Latib A
    Tex Heart Inst J; 2023 May; 50(3):. PubMed ID: 37302149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of oral P2Y
    Farmakis IT; Zafeiropoulos S; Doundoulakis I; Pagiantza A; Karagiannidis E; Moysidis DV; Stalikas N; Kassimis G; Michalis LK; Karvounis H; Giannakoulas G
    Open Heart; 2022 Apr; 9(1):. PubMed ID: 35428703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
    Ullah W; Zahid S; Sandhyavenu H; Faisaluddin M; Khalil F; Pasha AK; Alraies MC; Cuisset T; Rao SV; Sabouret P; Savage MP; Fischman DL
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):717-727. PubMed ID: 35325105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Zhao Z; Wang J; Lei M; Li Y; Yang Y; An L; Sun X; Li C; Xue Z
    BMC Cardiovasc Disord; 2023 Mar; 23(1):168. PubMed ID: 36991321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.